JP2004538319A - 抗−ｈｉｖ治療のためのｒ−ｎｓａｉｄ化合物の用途 - Google Patents

抗−ｈｉｖ治療のためのｒ−ｎｓａｉｄ化合物の用途 Download PDF

Info

Publication number
JP2004538319A
JP2004538319A JP2003518438A JP2003518438A JP2004538319A JP 2004538319 A JP2004538319 A JP 2004538319A JP 2003518438 A JP2003518438 A JP 2003518438A JP 2003518438 A JP2003518438 A JP 2003518438A JP 2004538319 A JP2004538319 A JP 2004538319A
Authority
JP
Japan
Prior art keywords
flurbiprofen
hiv
ester
pharmaceutically acceptable
nsaid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003518438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004538319A5 (https=
Inventor
ザヴィッツ，ケントン
Original Assignee
ミリアド・ジェネティックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミリアド・ジェネティックス・インコーポレイテッド filed Critical ミリアド・ジェネティックス・インコーポレイテッド
Publication of JP2004538319A publication Critical patent/JP2004538319A/ja
Publication of JP2004538319A5 publication Critical patent/JP2004538319A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2003518438A 2001-06-29 2002-07-01 抗−ｈｉｖ治療のためのｒ−ｎｓａｉｄ化合物の用途 Withdrawn JP2004538319A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30253301P 2001-06-29 2001-06-29
US10/186,371 US20030027867A1 (en) 2001-06-29 2002-06-28 Use of R-NSAID compounds for anti-HIV treatment
PCT/US2002/022289 WO2003013424A2 (en) 2001-06-29 2002-07-01 Use of r-nsaid compounds for anti-hiv treatment

Publications (2)

Publication Number Publication Date
JP2004538319A true JP2004538319A (ja) 2004-12-24
JP2004538319A5 JP2004538319A5 (https=) 2006-01-05

Family

ID=26882034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003518438A Withdrawn JP2004538319A (ja) 2001-06-29 2002-07-01 抗−ｈｉｖ治療のためのｒ−ｎｓａｉｄ化合物の用途

Country Status (6)

Country Link
US (1) US20030027867A1 (https=)
EP (1) EP1420745A2 (https=)
JP (1) JP2004538319A (https=)
AU (1) AU2002322481A1 (https=)
CA (1) CA2451691A1 (https=)
WO (1) WO2003013424A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510603A (ja) * 2002-10-07 2006-03-30 アンコール ファーマスーティカルズ インコーポレイテッド Ｒ−非ステロイド性抗炎症薬エステル及びそれらの使用
JP2009530306A (ja) * 2006-03-17 2009-08-27 アメリカ合衆国 脊髄性筋萎縮症の治療およびその他用途のための化合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
GB2475359A (en) * 2009-11-11 2011-05-18 Biocopea Ltd A compound for use in treating a fulminant respiratory disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1091403A (en) * 1964-01-24 1967-11-15 Boots Pure Drug Co Ltd Therapeutically active phenylalkane derivatives
FR1546478A (fr) * 1967-01-27 1968-11-22 Rhone Poulenc Sa Nouveaux dérivés de l'acide benzoyl-3 phénylacétique et leur préparation
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4230724A (en) * 1979-07-16 1980-10-28 Allergan Pharmaceuticals, Inc. Method of treating vascularization of the eye with Flurbiprofen
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH0610141B2 (ja) * 1986-02-14 1994-02-09 新技術事業団 エイズウイルス性疾患処置剤
DE3824353A1 (de) * 1988-07-19 1990-01-25 Paz Arzneimittelentwicklung Verfahren zur trennung von gemischen enantiomerer arylpropionsaeuren
JPH0248526A (ja) * 1988-08-08 1990-02-19 Sumitomo Pharmaceut Co Ltd インドメタシン注射剤およびその製造方法
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
DE69328838T2 (de) * 1992-03-13 2000-10-12 Sepracor Inc., Marlborough Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
DE4216756C2 (de) * 1992-05-21 1994-08-25 Pharmatrans Sanaq Ag 2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
DK169670B1 (da) * 1992-12-22 1995-01-09 Cheminova Agro As Fremgangsmåde til fremstilling af 2,3,5,6-tetrachlorpyridin
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5677469A (en) * 1995-05-18 1997-10-14 Sepracor, Inc. Process for resolving chiral acids with 1-aminoindan-2-ols
US5858738A (en) * 1996-11-07 1999-01-12 Merck & Co., Inc. Ermophilane sesquiterpenoids as HIV intergrase inhibitors
US6331610B1 (en) * 1997-04-25 2001-12-18 Metatron, Inc. Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
US6140349A (en) * 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
ATE353010T1 (de) * 1998-09-03 2007-02-15 Univ Loma Linda Med Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung
IN189741B (https=) * 1998-11-09 2003-04-19 Council Scient Ind Res

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510603A (ja) * 2002-10-07 2006-03-30 アンコール ファーマスーティカルズ インコーポレイテッド Ｒ−非ステロイド性抗炎症薬エステル及びそれらの使用
JP2009530306A (ja) * 2006-03-17 2009-08-27 アメリカ合衆国 脊髄性筋萎縮症の治療およびその他用途のための化合物

Also Published As

Publication number Publication date
AU2002322481A1 (en) 2003-02-24
WO2003013424A3 (en) 2004-02-12
US20030027867A1 (en) 2003-02-06
CA2451691A1 (en) 2003-02-20
EP1420745A2 (en) 2004-05-26
WO2003013424A2 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
DK173752B1 (da) Anvendelse af dihydroliponsyre til fremstilling af et lægemiddel til bekæmpelse af sygdomme fremkaldt af retrovirus.
JP2004538319A (ja) 抗−ｈｉｖ治療のためのｒ−ｎｓａｉｄ化合物の用途
ES2385819T3 (es) Combinación antirretroviral
US20010009906A1 (en) Use of 3&#39;-azido-2&#39; ,3&#39; -dideoxyuridine
JP2013216693A (ja) レトロウイルスの集合及び成熟の小分子阻害剤
BRPI9612992B1 (pt) Combinação, e, formulação farmacêutica
JP2011079840A (ja) Ｂ型肝炎治療のための組合せ療法
US9585849B2 (en) Broad spectrum antiviral and methods of use
JPS63310819A (ja) 抗レトロウイルス活性をもつ糖タンパク処理抑制剤
BRPI0610851A2 (pt) associação entre a ferroquina e um derivado de artemisinina, composição farmacêutica, utilização da referida associação e kit
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
SK129999A3 (en) Pharmaceutical composition, preparation process and use thereof
JP2648329B2 (ja) エイズの予防または治療用医薬組成物
US20060222628A1 (en) Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes and DNA viruses
US5519028A (en) Antiviral preparations
KR100294836B1 (ko) 바이러스감염증예방치료제
US7115584B2 (en) HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
EP2010166A2 (en) Organic thiophosphate antiretroviral agents
KR20010032055A (ko) Ａｉｄｓ 치료를 위한 혼합물 치료방법
WO2011046901A2 (en) Broad spectrum antiviral and methods of use
US7615542B2 (en) Dioxolane thymine and combinations for use against 3TC/AZT resistant strains of HIV
JPH03264530A (ja) 抗レトロウイルス剤
KR20000022225A (ko) Hiv 치료에 사용하기 위한 vx478, 지도부딘 및(또는)1592u89를 포함하는 배합물
JPH08208502A (ja) 抗エイズウイルス剤の効果増強剤
JPH07503252A (ja) 置換アザスペラン化合物投与によるｈｉｖ誘発エイズ遅延方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050627

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060428